Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial

INTRODUCTION: Patients with liver cirrhosis are often diagnosed late and once complications are present, the 2-year survival is 50%. Increasing evidence supports systemic inflammation and metabolic dysfunction in the hepatic stellate cell as key drivers of progression of cirrhosis. However, there is...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimer, Nina, Grønbæk, Henning, Fred, Rikard Gøran, Hansen, Torben, Deshmukh, Atul Shahaji, Mann, Mathias, Bendtsen, Flemming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Gastroenterology and Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045122/
https://www.ncbi.nlm.nih.gov/pubmed/31980514
http://dx.doi.org/10.1136/bmjopen-2019-035284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045122/
https://www.ncbi.nlm.nih.gov/pubmed/31980514
http://dx.doi.org/10.1136/bmjopen-2019-035284

Ejemplares similares